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Intrauterine growth restriction (IUGR) is associated with significantly increased perinatal morbidity and mortality as well as
cardiovascular disease and glucose intolerance in adult life. A number of disorders from genetic to metabolic, vascular, coagulative,
autoimmune, as well as infectious, can influence fetal growth by damaging the placenta, leading to IUGR as a result of many
possible fetal, placental and maternal disorders. Strict definitions of IUGR and of its severity are needed in order to eventually
distinguish among different phenotypes, such as gestational age at onset, degree of growth restriction and presence of hypoxia.
This report explores and reviews some of the most recent developments in both clinical and basic research on intrauterine
growth restriction, by seeking mechanisms that involve genetic factors, utero-placental nutrient availability and vascular growth
factors.
New exciting findings on the genomic imprinting defects potentially associated with IUGR, and the placental anomalies
associated with the decreased nutrient transport are summarized. Moreover, recent data on angiogenic growth factors as well as
new information arising from application of gene chip technologies are discussed.
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Intrauterine growth restriction (IUGR) presents a complex
management problem for the clinician. The failure of a fetus to
achieve its genetically determined growth potential is associ-
ated with significantly increased perinatal morbidity and mor-
tality [1] as well as being a major determinant of cardiovascular
disease and glucose intolerance in adult life [2].
IUGR is not a specific disease entity with a unique patho-
physiology, but the result of suboptimal intrauterine growth
conditions in conjunction with a variety of disorders from
genetic to metabolic, vascular, coagulative, autoimmune, as well
as infectious. New challenging fields, like genomic imprinting
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2003 in Mainz, Germany.
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E-mail address: irene.cetin@unimi.it (I. Cetin).0143–4004/$–see front matterdefects potentially involved in regulation of fetal and placen-
tal growth, or trombophilic diseases potentially damaging the
placenta are now being explored and may represent additional
causes of IUGR.
Understanding the etiology of IUGR in each specific preg-
nancy is the basis for the clinical management of that patient.
Fetal growth is a complex process regulated by genetic factors,
utero-placental nutrient availability and hormones. However,
independently from the underlying cause, a fetus that fails to
achieve its full growth potential has, by definition, undergone
a process of reduced tissue deposition due to a reduced nutri-
tional supply from the utero-placental circulation (Figure 1).
While the knowledge of IUGR resulting from a shallow
trophoblast invasion during the first trimester, together with
Doppler studies showing changes in the utero-placental cir-
culation, is widespread among both clinicians and scientists,
the discoveries that the nutrient supply can also be decreased
by changes in the placental transport properties is not so well
known. Moreover, recent studies in a number of mouse knock-
out and transgenic models have allowed to link defects in 2004 Elsevier Ltd. All rights reserved.
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However, the lessons of the murine experiments need to be
compared to results obtained in human pregnancies. We will
briefly review some of the most recent developments in both
clinical and basic research on intrauterine growth restriction.
In particular, we will describe advances in clinical under-
standing of the natural history of IUGR, the genomic im-
printing defects potentially associated with IUGR, and the
placental anomalies possibly responsible for the decreased
nutrient transport. We will also summarize new results demon-
strating involvement of angiogenic growth factors in the
pathogenesis of preeclampsia and IUGR.
CRITERIA FOR DIAGNOSIS AND EVALUATION
OF SEVERITY OF IUGR
There is still considerable debate as to how IUGR should be
defined. The most commonly used definition is based on a
birth weight below the 10th percentile. However, a significant
number of small-for-gestational age babies (SGA) is not truly
growth restricted and is instead part of the normal variation
in the birth weight distribution. Therefore, we should include
the evaluation of growth in utero, for example as a defined
shift in centiles on a standard growth curve of the routine
ultrasound measurements in the definition of a population of
truly growth-restricted fetuses. However, in large population
studies, in utero diagnosis might not be available, and a pop-
ulation of SGA is often utilized. This is acceptable as long as
explained and recognized as a study limitation.
Assessment of intrauterine growth is particularly relevant
for diagnosis of IUGR early in gestation. Diagnosis of IUGR
during pregnancy before 32 weeks of gestation might result in
babies having a weight over the 10th percentile at birth. There
are two potential reasons for this discrepancy. 1. In conven-
tional birth weight curves, the assumption that the weight-for-
gestation profile of babies born prematurely represents that of
the healthy babies who continue to grow in utero might be
incorrect [4]. 2. Alterations in growth occurring early in
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Figure 1. Mechanisms for reduced tissue deposition in fetal growth
restriction.gestation might lead to a very sick baby before the weight falls
below the 10th centile.
This again underlines the need for endpoints that allow
for definitions of severity. There are three main general deter-
minants of severity: 1. gestational age, 2. degree of nutritional
deprivation, and 3. degree of oxygenation.
All these parameters are associated with short- and long-
term adverse outcome. However, the prognosis for neurolog-
ical function is strictly related to oxygenation and adequate
timing of delivery. Not all IUGR fetuses are subjected to
a reduced oxygen supply [5]. Fetuses that exhibit normal
umbilical arterial blood flows evaluated by Doppler blood
velocimetry and normal fetal heart rate are indeed associated
with normal oxygenation [5]. Recently, a temporal sequence of
early and late Doppler velocimetry alterations which occur in
a subset of early and severe IUGR fetuses has been described
[6]. Abnormalities of the pulsatility index of the middle
cerebral artery and of the umbilical artery (absent end diastolic
flow) represent early changes that precede blood flow abnor-
malities of the ductus venosus, reverse end-diastolic flow of the
umbilical artery, decreased pulmonary artery peak velocity,
reverse flow in the ductus venosus and, lastly, decreased aortic
peak velocity, which represent ‘‘late’’ changes, associated with
an increased risk of perinatal death [6].
GENOMIC IMPRINTING DEFECTS AND IUGR
There is a strong association between abnormal fetal karyo-
type, Mendelian single gene disorders, uniparental disomies
(UPDs) and IUGR. Fetal genetic changes include trisomies of
chromosomes 13, 18 and 21, microdeletions, confined placental
mosaicism and more than 50 inherited single gene disorders.
The risks associated with UPDs include genetic dysfunction if
the chromosomal segment involved harbours imprinted genes.
IUGR is the most common feature, a phenotype shared among
matUPD7, matUPD14, patUPD6q24 and matUPD20. The
fetal growth disturbance in UPD carriers is consistent with the
action of imprinted genes during fetal growth, as recently
reviewed [7]. In murine models, most of the 60 recognized
imprinted genes are expressed during fetal life and, in par-
ticular, in the placenta, in which they may regulate fetal
demand and maternal supply of nutrients. This peculiar mech-
anism of growth regulation has been demonstrated for Igf2 in
mice lacking specific Igf2 placental transcript [3].
There are many mouse models in which targeted candidate
gene mutations result in compromised placental function and
IUGR, although the pathological effects differ among the
investigated genes. ESX1 mutants show changes of vascular-
ization in the placental labyrinth [8], Igf2 null mice have an
inefficient placental transport [3], and p57/Kip2-deficient
mice present changes of labyrinth and spongiotrophoblast [9].
Data from murine models strongly indicate that IUGR cannot
be considered a disease per se, rather a manifestation of many
possible fetal gene defects that primarily affect placental devel-
opment and function. The reverse approach (from phenotype
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human IUGR fetuses are complicated by the heterogeneity of
predisposing causes. A useful approach could be to segregate
the IUGR cases in different sub-phenotypes, as recently sug-
gested by Cross [10] for human preeclampsia. In this view it
could be helpful to evaluate the severity of IUGR [5], placental
morphology and additional pregnancy complications such as
preeclampsia. Finally, in order to focus on possible genetic
causes of IUGR it is important to take into account and in-
vestigate a familial aggregation of IUGR by assessing a detailed
pedigree analysis.
PLACENTAL TRANSPORT
In the human placenta, it is the two plasma membranes of
the syncytiotrophoblast that represent the primary barrier to
transport of glucose, amino acids and most ions. Consequently,
studies of isolated microvillous (MVM) and basal plasma
membranes (BM) may provide valuable information concern-
ing transplacental transport processes. In MVM isolated from
small-for gestational age babies the activity of the amino acid
transporter system A was shown to be markedly reduced [11].
Intrauterine growth restriction is also associated with a reduced
activity/expression of placental transport systems for essential
amino acids, such as taurine, leucine and cationic amino acids.
In contrast to the effect of IUGR on placental amino acid
transport the expression and activity of glucose transporters is
unaltered in IUGR [12].
Placental ion transporters also appear to be altered in IUGR.
For example, the activity and protein expression of the Na+/
K+ ATPase in the MVM, but not BM, is reduced in the
IUGR placenta [13]. It is possible that this change may impair
the ability of the syncytiotrophoblast to maintain a low intra-
cellular Na+ concentration, thereby affecting all Na+-coupled
transport processes. Furthermore, the activity and protein ex-
pression of the Na+/H+ exchanger in MVM, the primary
mechanism for syncytiotrophoblast pH regulation, is dimin-
ished in preterm, but not in term IUGR [14]. It is speculated
that these alterations may contribute to the development of
acidosis in the IUGR fetus delivered preterm. Interestingly,
the activity of the Ca2+ ATPase in BM has been shown to be
markedly increased in association with IUGR [15].
Collectively, these in vitro data clearly suggest that IUGR is
associated with a number of changes in the activity and/or
expression of placental nutrient and ion transporters. These
alterations may be present also in vivo as shown by the recent
demonstration of decreased transplacental transport of leucine
in human pregnancies complicated by IUGR [16].
The changes observed in IUGR are likely to be specific and
not secondary to a general pathological process such as altered
membrane composition. Some of the observed changes, for
example, the reduction in amino acid transporter activity, may
be ‘‘primary’’ events in the development of IUGRwhereas other
alterations, e.g., increasedCa2+ATPase activity,may be second-
ary to restricted fetal growth. There are also new possibilitiesemerging as the molecular characterization of nutrient trans-
porters progresses. For both glucose and amino acid trans-
porters the concept of a single transporter is being displaced as
multiple isoforms of a transporter are defined. If these isoforms
have different properties, altered isoform ratios or distribution
may have significant effects on activity in vivo. For example the
system L amino acids transporter has two isoforms; the first,
LAT-1, is an exchange transporter [17], while there are reports
that the second, LAT-2, is a uniporter [18]. Changes in the
isoform ratio might have significant effects on transport without
apparent changes in overall transporter expression.
It is speculated that the placenta functions as a ‘‘nutritional
sensor’’ and responds to changes in maternal nutrition or
placental blood flow by altering the activity and/or expression
of placental nutrient transporters, thereby regulating fetal
growth. There is however an equally powerful argument to be
made that the fetus, as the ‘‘end-user’’ of nutrients transported
across the placenta, may also act as the nutritional sensor
through output of hormones controlling fetal (and possibly
placental) growth by circulating nutrient concentrations.
EXPRESSION OF VEGF, PlGF AND
THEIR RECEPTORS IN PREGNANCIES
COMPLICATED BY PREECLAMPSIA
AND IUGR
Several growth factors such as vascular endothelial growth
factor (VEGF-A) and placental growth factor (PlGF) are
involved in placental vascular development. Therefore, it is of
interest to understand whether dysregulation in the VEGF
family may be associated with preeclampsia and IUGR. Recent
studies show evidence for a significant deregulation of the
expression of VEGF, PlGF and their receptors in the placenta
of severe early onset preeclampsia or IUGR [19].
VEGF-A, PlGF and VEGFR-1 that are produced by villous
and extravillous trophoblast cells are significantly upregulated
in placentas from preeclamptic women and from cases with
IUGR [19,20]. It seems that during pregnancy most of the
circulating VEGF is bound to sVEGFR-1 produced in high
amounts by the placenta [19–21]. In preeclampsia, placental
production of VEGFR-1 and sVEGFR-1 is likely increased
because of low oxygen levels in the placenta. The massive
increase of sVEGFR-1 in preeclamptic women results in low
levels of circulating free VEGF and free PlGF.
Results from the placental bed biopsies show that VEGFR-1
expression is significantly reduced in cases with preeclampsia.
Low levels of VEGFR-1 in the placental bed may explain the
defective uterine vascularization frequently associated with
early onset preeclampsia. Maynard et al. [20] have shown in
a rodent model that VEGF, PlGF and sVEGFR-1 are likely to
play a role in the pathogenesis of preeclampsia. Excess
placental production of sVEGFR-1 contributes to hyperten-
sion, proteinuria and glomerular endotheliosis.
In conclusion, these studies indicate the involvement of
sVEGFR-1 as an antagonist to VEGF and PlGF in
756 Placenta (2004), Vol. 25preeclampsia. The downregulation of the membrane bound
form of VEGFR-1 in the placental bed may also result in the
decreased maternal vascular adaptation to pregnancy.
NEW DEVELOPMENTS OF THE GENE CHIP
STUDIES APPROACH
New areas, like gene chip studies fishing for new genes,
are exploring still unknown possibilities. These preliminary
studies reveal that genes involved in lipid metabolism are being
differentially upregulated in the growth-restricted group.
Moreover, few other genes that have not been associated with
IUGR before have been found to have expression levels that
are markedly different in IUGR.
Aberrant gene expression in the placenta of IUGR preg-
nancies has been investigated on pooled RNA purified from
tissue biopsies taken at term [22]. The expression profiles have
been analysed by microarrays (Human Genome U133A,
Affimetrix) and the expression levels of a selection of genes
verified by real-time PCR. A number of genes implicated in
lipid metabolism were differentially expressed in IUGR
placentas. Among these, lipoprotein receptors (VLDL-ApoE),
lipoprotein lipase (LPL), fatty acid-binding protein 4 (FABP4)
and intracellular lipase activities are involved in the transport
of fatty acids from the maternal circulation across the placenta.
These changes might therefore modify the placental delivery
of fatty acids to the fetus in a critical period when fat is
deposited exponentially. This is in agreement with the differ-
ent profile of polyunsaturated fatty acids that has been re-
ported in IUGR [23].
sVEGFR has also been found to be upregulated in cases of
IUGR. Soluble VEGFR has a higher affinity for VEGF than
VEGFR and it has been hypothesized that it may function as
an inhibitor of the cellular VEGF response [24]. This study
also identified caveolins as potential factors implicated in
IUGR.
Further investigations are needed to detail the significance
and the role of the differentially expressed genes identified by
the array analysis. In particular, two main issues are under
discussion: technical relevance and placental function. The
first issue challenges the reproducibility, sensitivity and
accuracy of microarray results. One major concern is the
variability of tissue biopsies, which is intrinsic to tissue
heterogeneity but also results from sampling procedures. This
is particularly relevant for the human placenta at term because
of its size and composite structure. Hence, multiple variables
have to be taken into account when comparing microarray
results either from intra-experiments as well as results from
different investigators. Phenotype classification and analytical
strategy should also be taken into account since they determine
the final number of genes eligible for comparison, a variable
that happens to vary tremendously (from less than ten to
several hundred genes) depending on investigators, experi-
mental settings and procedures.
The second main issue is regarding the functional
significance of the genes whose expression is reported to bemodified in placenta of growth-restricted fetuses. Three of
these genes are involved in the transport of fatty acids from the
maternal circulation across the placenta. Since the changes
suggest an increased supply of fatty acids to the fetus in spite
of low fetal adiposity and despite results in vivo demonstrating
reduced feto-maternal relationships for the long-chain poly-
unsaturated fatty acids [23], the question arises whether this
could represent an adaptation of placental transfer function to
compensate for poor fetal growth. Whether compensatory
mechanisms should be regarded as tentative explanations when
experimental results are contrary to physiological/biochemical
expectations is a matter of debate.
CONCLUSIONS
In the last decades, thanks to new technologies like ultrasound
and fetal blood sampling we have learned a lot more about
development of the fetus and abnormalities of its growth
trajectory leading to IUGR. Moreover, the placental mecha-
nisms involved in this pathology are starting to be understood.
However, although this progress has led to improvements in
diagnosis and understanding, we are still in the situation of no
reasonable therapy during pregnancy, optimal timing of
delivery still representing the only available intervention in
order to reduce adverse pregnancy outcomes. Further efforts
are needed to utilize this body of new information in the
development of novel therapeutic strategies.
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